News | February 09, 2024
Spriya Lifescience Q3 FY24 PAT jumps 213% at Rs. 29.79 Cr
EBITDA for Q3 FY24 almost tripled to reach Rs. 41.49 crore
EBITDA for Q3 FY24 almost tripled to reach Rs. 41.49 crore
The company recently received CEP certificate approval for Losartan Potassium by EDQM
Developed by Pfizer, Abrocitinib has received marketing authorization from the Central Drugs Standard Control Organization (CDSCO) in India
Glenmark will be responsible for further developing, registering, and commercializing Envafolimab in India, Asia Pacific, Middle East and Africa, Russia, CIS, and Latin America
The company intends to respond to the two minor observations within the stipulated time
The registered capital of the newly founded company is € 50 million
Glenmark Life Sciences will manufacture API in the therapeutic area of urinary anti-spasmodic, to supply to the global innovator
Agreed Price of US$43 per share to deliver 48% premium to unaffected price on May 25, 2023
Microdosing has emerged as a key trend in the pharmaceutical and nutritional markets
A 'better for you' organic brand spanning Food & Beverages and Nutraceutical categories
Subscribe To Our Newsletter & Stay Updated
